Nonstatin Therapies for Management of Dyslipidemia: A Review

Clinical Therapeutics

Volumn 37, Issue 10, 2015, Pages 2153-2179

  Sando, Karen R ^a   Knight, Michelle ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

bile acid sequestrant; ezetimibe; fenofibrate; Key words non statin therapy; niacin; omega 3 fatty acid

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOFIBRATE; HYPOCHOLESTEROLEMIC AGENT; KEX2 PROTEIN, S CEREVISIAE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SACCHAROMYCES CEREVISIAE PROTEIN; SERINE PROTEINASE;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; META ANALYSIS; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES; VASCULAR SURGERY; BLOOD; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; DYSLIPIDEMIAS; METABOLISM; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; CLOFIBRATE; DISEASE MANAGEMENT; DYSLIPIDEMIAS; EZETIMIBE; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; PROPROTEIN CONVERTASES; RISK FACTORS; SACCHAROMYCES CEREVISIAE PROTEINS; TRIGLYCERIDES; UNITED STATES;

EID: 84944745204     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.09.001     Document Type: Review

References (138)

1. National Center for Chronic Disease Prevention and Health Promotion. Heart Disease and Stroke Prevention: Addressing the National's Leading Killers. At a Glance (2011). Centers for Disease Control. http://198.246.124.29/chronicdisease/resources/publications/aag/pdf/2011/heart-disease-and-stroke-aag-2011.pdf. Accessed April 20, 2015.
2. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines J Am Coll Cardiol 63 2014 2889 2934
3. T.A. Jacobson, M.K. Ito, K.C. Maki, and et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - Executive Summary J Clin Lipidol 8 2014 473 488
4. National Cholesterol Education Program (NCEP) Expert Panel Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Circulation 106 2002 3143 3421
5. The Risk and Prevention Study Collaborative Group N-3 fatty acids in patients with multiple cardiovascular risk factors N Engl J Med 368 2013 1800 1808
6. S. Parish, J. Tomson, K. Wallendszus, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
7. H.N. Ginsberg, M.B. Elam, L.C. Lovato, et al. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
8. V.S. Kamanna, and M.L. Kashyap Mechanism of action of niacin Am J Cardiol 101 2008 20B 26B
9. Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
10. P.L. Canner, K.G. Berge, N.K. Wenger, and et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
11. L.A. Carlson, and G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
12. D.H. Blankenhorn, S.A. Nessim, R.L. Johnson, and et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 1987 3233 3240
13. L. Cashin-Hemphill, W.J. Mack, J.M. Pogoda, and et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up JAMA 264 1990 3013 3017
14. G. Brown, J.J. Albers, L.D. Fisher, and et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 325 1991 599 605
15. B.G. Brown, Z. Xue-Qiao, A. Chait, and et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
16. A.J. Taylor, L.E. Sullenberger, H.J. Lee, and et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
17. A.J. Taylor, T.C. Villines, E.J. Stanek, and et al. Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
18. E.J. Whitney, R.A. Krasuski, B.E. Personius, and et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events Ann Intern Med 142 2005 95 104
19. W. Boden, J. Probstfield, T. Anderson, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
20. J.K. Duggal, M. Singh, N. Attri, and et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease J Cardiovasc Pharmacol Ther 15 2010 158 166
21. K.K. Teo, L.B. Goldstein, B.R. Chaitman, and et al. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease-the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/high triglycerides: impact on global health outcome (AIM-HIGH) trial Stroke 44 2013 2688 2693
22. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression J Am Coll Cardiol 61 2013 440 446
23. H.E. Bays, A.P. Tighe, R. Sadovsky, and M.H. Davidson Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications Expert Rev Cardiovasc Ther 6 2008 391 409
24. J.C. Bradberry, and D.E. Hilleman Overview of omega-3 fatty acid therapies PT 38 2013 681 691
25. C.J. Lavie, R.V. Milani, M.R. Mehra, and H.O. Ventura Omega-3 polyunsaturated fatty acids and cardiovascular diseases J Am Coll Cardiol 54 2009 585 594
26. S.M. Grundy, J.I. Cleeman, M.C.N. Bairey, and et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
27. L. Berglund, J.D. Brunzell, A.C. Goldberg, and et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 97 2012 2969 2989
28. C.R. Harper, and T.A. Jacobson Usefulness of omega-3 fatty acids and the prevention of coronary heart disease Am J Cardiol 96 2005 1521 1529
29. C. Wang, W.S. Harris, M. Chung, and et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review Am J Clin Nutr 84 2006 5 17
30. J.M. Geleijnse, J. De Goede, and I.A. Brouwer Alpha-linolenic acid: is it essential to cardiovascular health? Curr Atheroscler Rep 12 2010 359 367
31. A. Zargar, and M.K. Ito Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database Metab Syndr Relat Disord 9 2011 255 271
32. H.S. Weintraub Overview of prescription omega-3 fatty acid products for hypertriglyceridemia Postgrad Med 126 2014 7 18
33. M.L. Burr, A.M. Fehily, J.F. Gilbert, and et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART) Lancet 2 1989 757 761
34. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the gissi-prevenzione trial. Gruppo Italiano per lo Studio Della Sopravvivenza Nell'infarto Miocardico Lancet 354 1999 447 455
35. M.L. Burr, P.A. Ashfield-Watt, F.D. Dunstan, and et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial Eur J Clin Nutr 57 2003 193 200
36. M. Yokoyama, H. Origasa, M. Matsuzaki, and et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
37. L. Tavazzi, A.P. Maggioni, R. Marchioli, and et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1223 1230
38. D. Kromhout, E.J. Giltay, and J.M. Geleijnse N-3 fatty acids and cardiovascular events after myocardial infarction N Engl J Med 363 2010 2015 2026
39. B. Rauch, R. Schiele, S. Schneider, and et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction Circulation 122 2010 2152 2159
40. P. Galan, E. Kesse-Guyot, S. Czernichow, and et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial BMJ 341 2010 c6273
41. The ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 367 2012 309 318
42. F.B. Hu, L. Bronner, W.C. Willett, and et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women JAMA 287 2002 1815 1821
43. C.M. Albert, C.H. Hennekens, C.J. O'Donnell, and et al. Fish consumption and risk of sudden cardiac death JAMA 279 1998 23 28
44. J.H.Y. Wu, and D. Mozaffarian ω-3 Fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle Heart 100 2014 530 533
45. Q. Chen, L.-Q. Cheng, T.-H. Xiao, and et al. Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials Cardiovasc Drugs Ther 25 2011 259 265
46. J. Hartweg, R. Perera, V. Montori, and et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus Cochrane Database Syst Rev 2008 Issue 1. Art No:D003205
47. E.C. Rizos, E.E. Ntzani, E. Bika, and et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis JAMA 308 2012 1024 1033
48. S.M. Kwak, S.-K. Myung, Y.J. Lee, and H.G. Seo Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials Arch Intern Med 172 2012 686 694
49. S. Kotwal, M. Jun, D. Sullivan, and et al. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis Circ Cardiovasc Qual Outcomes 5 2012 808 818
50. A. Gupta, V. Guyomard, M.J.S. Zaman, and et al. Systematic review on evidence of the effectiveness of cholesterol-lowering drugs Adv Ther 27 2010 348 364
51. K.B. Filion, F. El Khoury, M. Bielinski, and et al. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials BMC Cardiovasc Disord 10 2010 24
52. J.E. Enns, A. Yeganeh, R. Zarychanski, and et al. The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis BMC Cardiovasc Disord 14 2014 70
53. R. Chowdhury, S. Stevens, D. Gorman, and et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis BMJ 345 2012 e6698
54. D. Yzebe, and M. Lievre Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials Fundam Clin Pharmacol 18 2004 581 592
55. L. Hooper, R.A. Harrison, C.D. Summerbell, and et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease Cochrane Database Syst Rev 2004 Issue 4. Art. No:CD003177
56. M. Studer, M. Briel, B. Leimenstoll, and et al. Effect of different antilipidemic agents and diets on mortality: a systematic review Arch Intern Med 165 2005 725 730
57. Y.-T. Zhao, Q. Chen, Y.-X. Sun, and et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials Ann Med 41 2009 301 310
58. J. Delgado-Lista, P. Perez-Martinez, J. Lopez-Miranda, and F. Perez-Jimenez Long chain omega-3 fatty acids and cardiovascular disease: a systematic review Br J Nutr 107 2012 S201 S213
59. M.N.D. Di Minno, E. Tremoli, A. Tufano, and et al. Exploring newer cardioprotective strategies: n-3 fatty acids in perspective Thromb Haemost 104 2010 664 680
60. N. Khoury, and A.C. Goldberg The use of fibric acid derivatives in cardiovascular prevention Curr Treat Options Cardiovasc Med 13 2011 335 342
61. P. Goyal, L.I. Igel, K. LaScalea, and W.B. Borden Cardiometabolic impact of non-statin lipid lowering therapies Curr Atheroscler Rep 16 2014 390
62. Z. Reiner Combined therapy in the treatment of dyslipidemia Fundam Clin Pharmacol 24 2010 19 28
63. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
64. M.H. Frick, O. Elo, K. Haapa, and et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia N Engl J Med 317 1987 1237 1245
65. H.B. Rubins, S.J. Robins, D. Collins, and et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
66. A. Keech, R.J. Simes, P. Barter, and et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial Lancet 366 2005 1849 1861
67. J.B. Arthur, RB Raffle, WR Ashby, and et al. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region BMJ 4 1971 767 775
68. Research Committee of the Scottish Society of Physicians Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians BMJ 4 1971 775 784
69. J. Acheson, and E.C. Hutchinson Controlled trial of clofibrate in cerebral vascular disease Atherosclerosis 15 1972 177 183
70. The Veterans Administration Cooperative Study Group The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section Stroke 4 1973 684 693
71. WHO Cooperative trial committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators Br Heart J 40 1978 1069 1118
72. M. Hanefeld, S. Fischer, H. Schmechel, and et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM Diabetes Care 14 1991 308 317
73. L. Tenkanen, M. Manttari, and V. Manninen Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study Circulation 92 1995 1779 1785
74. M. Jun, C. Foote, J. Lv, and et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
75. R.S. Birjmohun, B.A. Hutten, and J.J.P. Kastelein Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol 45 2005 185 197
76. S. Allemann, P. Diem, M. Egger, and et al. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials Curr Med Res Opin 22 2006 617 623
77. M. Jun, B. Zhu, M. Tonelli, and et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis J Am Coll Cardiol 60 2012 2061 2071
78. S. Abourbih, K.B. Filion, L. Joseph, and et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review Am J Med 122 2009 962.e1 962.e8
79. D. Keene, C. Price, M.J. Shun-Shin, and D.P. Francis Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients BMJ 349 2014 g4379
80. Kimberly A Gudzune, K. Monroe Anne, R. Sharma, and et al. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy Ann Intern Med 160 2014 468 476
81. M. Studer, M. Briel, B. Leimenstoll, and et al. Effect of different antilipidemic agents and diets on mortality: a systematic review Arch Intern Med 165 2005 725 730
82. S.A. Saha, and R.R. Arora Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - a pooled meta-analysis of randomized placebo-controlled clinical trials Int J Cardiol 141 2010 157 166
83. J.-C. Corvol, A. Bouzamondo, M. Sirol, and et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials Arch Intern Med 163 2003 669 676
84. Y.H. Zhou, X.F. Ye, F.F. Yu, and et al. Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention BMC Neurol 13 2013 1
85. M. Lee, J.L. Saver, A. Towfighi, and et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis Atherosclerosis 217 2011 492 498
86. E. Bruckert, J. Labreuche, D. Deplanque, and et al. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis J Cardiovasc Pharmacol 57 2011 267 272
87. A.J. Nordmann, I. Ferreira-González, B. Kasenda, and et al. Fibrates for primary prevention of cardiovascular disease events Cochrane Database Syst Rev 2012 Issue 3. Art No:CD009753
88. K. Einarsson, S. Ericsson, S. Ewerth, and et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism Eur J Clin Pharmacol 40 Suppl 1 1991 S53 S58
89. Monroe AK, Gudzune KA, Sharma R, et al. Combination Therapy Versus Intensification of Statin Monotherapy: An Update, Comparative Effectiveness Review No 132. AHRQ Publication No. 14-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality; February 2014. http://www.ncbi.nlm.nih.gov/books/NBK189822/. Accessed April 22, 2015.
90. S.J. Kamal-Bahl, T. Burke, D. Watson, and C. Wentworth Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice Am J Cardiol 99 2007 530 534
91. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II The relationship of reduction in incidence of coronary heart disease to cholesterol lowering JAMA 251 1984 365 374
92. A.E. Dorr, K. Gundersen, J. Schneider, and et al. Colestipol hydrochloride in hypercholesteroleamic patients- effect on serum cholesterol and mortality J Chronic Dis 31 1978 5 14
93. H.G. Schrott, E.A. Stein, C.A. Du, and et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy Am J Cardiol 75 1995 34 39
94. H.H. Knapp, H. Schrott, P. Ma, and et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia Am J Med 110 2001 352 360
95. D. Hunninghake, W. Insull, P. Toth, and et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively Atherosclerosis 158 2001 407 416
96. Pravastatin Multicenter Group II Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia Arch Intern Med 153 1993 1321 1329
97. F. Ismail, C.N. Corder, S. Epstein, and et al. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites Clin Ther 12 1990 427 430
98. G. Barbi, C.N. Corder, E. Koren, and et al. Effect of pravastatin and cholestyramine on triglyceride-rich lipoprotein particles and Lp(a) in patients with type II hypercholesterolemia Drug Development Res 27 1992 297 306
99. J. Johansson Low-dose combination therapy with colestipol and simvastatin in patients with moderate to severe hypercholesterolemia Nutr Metab Cardiovasc Dis 5 1995 39 44
100. E. Lioudaki, E. Ganotakis, and D. Mikhailidis Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years Curr Vasc Pharmacol 9 2011 62 86
101. G.N. Kouvelos, E.M. Arnaoutoglou, M.I. Matsagkas, and et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study J Cardiovasc Pharmacol Ther 18 2012 5 12
102. M. Sharma, M.T. Ansari, A.M. Abou-setta, and K. Soares-weiser Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia Ann Intern Med 151 2009 622 630
103. L. Luo, X. Yuan, W. Huang, and et al. Safety and coadministration of ezetimibe and statins in patients with hypercholesterolemia: a meta-analysis Intern Med J 45 2015 546 557
104. A.B. Rossebo, T.R. Pedersen, C. Allen, and et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study Am J Cardiol 99 2007 970 973
105. C. Baigent, M.J. Landray, C. Reith, and et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
106. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397
107. A. Upadhyay, A. Earley, J. Lamont, and et al. Lipid-lowering therapy in persons with chronic kidney disease Ann Intern Med 157 2012 251 262
108. D.J. Gordon, J.L. Probstfield, R.J. Garrison, and et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
109. P.C.N. Rensen, and L.M. Havekes Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport? Arterioscler Thromb Vasc Biol 26 2006 681 684
110. J.J.P. Kastelein, S.I. van Leuven, L. Burgess, and et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
111. M.L. Bots, F.L. Visseren, G.W. Evans, and et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 2007 153 160
112. S.E. Nissen, J.C. Tardif, S.J. Nicholls, and et al. Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316
113. P.J. Barter, M. Caulfield, M. Eriksson, and et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
114. Z.A. Fayad, V. Mani, M. Woodward, and et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Lancet 378 2011 1547 1559
115. T.F. Lüscher, S. Taddei, J.-C. Kaski, and et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial Eur Heart J 33 2012 857 865
116. G.G. Schwartz, A.G. Olsson, M. Abt, and et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
117. C.P. Cannon, S. Shah, H.M. Dansky, and et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
118. M. Ranalletta, K.K. Bierilo, Y. Chen, and et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors J Lipid Res 51 2010 2739 2752
119. R. Krishna, M.S. Anderson, A.J. Bergman, and et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914
120. D. Bloomfield, G.L. Carlson, A. Sapre, and et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am Heart J 157 2009 352 360
121. G. Cao, T.P. Beyer, Y. Zhang, and et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure J Lipid Res 52 2011 2169 2176
122. S.J. Nicholls, H.B. Brewer, J.J.P. Kastelein, and et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
123. N.G. Seidah, S. Benjannet, L. Wickham, and et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation Proc Natl Acad Sci USA 100 2003 928 933
124. P. Stawowy, I.A. Just, and E. Kaschina Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia Coron Artery Dis 25 2014 353 359
125. C. Werner, M.M. Hoffmann, K. Winkler, and et al. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment Vascul Pharmacol 62 2014 94 102
126. A.V. Khera, A. Qamar, M.P. Reilly, and et al. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia Am J Cardiol 115 2015 178 182
127. M. Farnier PCSK9: From discovery to therapeutic applications Arch Cardiovasc Dis 107 2014 58 66
128. A.L. Catapano, and N. Papadopoulos The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway Atherosclerosis 228 2013 18 28
129. E.A. Stein, D. Gipe, J. Bergeron, and et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
130. E.M. Roth, J.M. McKenney, C. Hanotin, and et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
131. J.M. McKenney, M.J. Koren, D.J. Kereiakes, and et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
132. R.P. Giugliano, N. Desai, P. Kohli, and et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
133. M.J. Koren, R. Scott, J.B. Kim, and et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
134. D. Sullivan, A.G. Olsson, R. Scott, and et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
135. F. Raal, R. Scott, R. Somaratne, and et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
136. C.M. Ballantyne, J. Neutel, A. Cropp, and et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia Am J Cardiol 115 2015 1212 1221
137. J.G. Robinson, M. Farnier, M. Krempf, and et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1489 1499
138. M.S. Sabatine, R.P. Giugliano, S.D. Wiviott, and et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1500 1509